Fulvestrant in heavily pre-treated patients with advanced breast cancer: Results from a single compassionate use programme centre

Breast Cancer Research and Treatment

Volumn 106, Issue 1, 2007, Pages 97-103

  Catania, Chiara ^a   Ascione, Gilda ^a   Adamoli, Laura ^a   De Pas, Tommaso ^a   Medici, Marta ^a   Franceschelli, Lucia ^a   Verri, Elena ^a   Magni, Elena ^a   Sanna, Giuseppina ^a   Torrisi, Rosalba ^a   Goldhirsch, Aron ^a   Nolè, Franco ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Breast cancer; Endocrine treatment; Fulvestrant; Postmenopausal

Indexed keywords

ESTROGEN RECEPTOR; FULVESTRANT; PROGESTERONE RECEPTOR;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ARTICLE; ASTHENIA; BONE PAIN; BREAST CANCER; CANCER GRADING; CANCER GROWTH; CONSTIPATION; CONTROLLED STUDY; DATA ANALYSIS; DISEASE COURSE; FEMALE; HORMONAL THERAPY; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MYALGIA; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; EMPATHY; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MIDDLE AGED; PROGRAM EVALUATION; PROSPECTIVE STUDIES; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TIME FACTORS; TREATMENT OUTCOME;

EID: 34848858288     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-006-9481-8     Document Type: Article

References (21)

1. Goldhirsch A, Gelber R (1996) Endocrine therapies of breast cancer. Semin Oncol 23:494-505
2. Hortobagyi GN (1998) Progress in endocrine therapy for breast carcinoma. Cancer 83:1-6
3. Buzdar AU, Hortobagyi G (1998) Update on endocrine therapy for breast cancer. Clin Cancer Res 4:527-534
4. Johnston SR, Martin AL, Dowset M (2005) Life following aromatase inhibitors: where now for endocrine sequencing? Breast Cancer Res Treat 93(Suppl 1):S19-S25
5. Howell A, Osborne CK, Morris C et al (2000) ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen. Cancer 89:817-825
6. Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG et al (1995) Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst 87:746-750
7. Addo S, Yates RA, Laight A (2002) A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers. Br J Cancer 87:1354-1359
8. Howell A, Robertson J (1995) Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet 345:989-990
9. Howell A, DeFriend DJ, Robertson JF et al (1996) Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer. Br J Cancer 74:300-308
10. Osborne CK, Pippen J, Jones SE et al (2002) Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 20:3386-3395
11. Howell A, Robertson JFR, Quaresma Albano J et al (2002) Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 20:3396-3403
12. Howell A, Pippen J, Elledge RM et al (2005) Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials. Cancer 104:236-239
13. Robertson JF, Osborne CK, Howell A et al (2003) Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women-a prospective combined analysis of two multicenter trials. Cancer 98:229-238
14. Franco S, Perez A, Tan-Chiu E et al (2004) Response to fulvestrant in heavily pretreated postmenopausal women: a single-center experience. Breast Cancer Res Treat 88:103-108
15. Steger GG, Bartsch R, Wenzel C et al (2005) Fulvestrant ('Faslodex') in pre-treated patients with advanced breast cancer: a single-centre experience. Eur J Cancer 41:2655-2661
16. Steger GG, Gips M, Simon SD et al (2005) Fulvestrant ('Faslodex'): clinical experience from the compassionate use programme. Cancer Treat Rev 31(Suppl 2):S10-S16
17. Ingle JN, Suman VJ, Rowland KM et al (2006) Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: north central cancer treatment group trial n0032. J Clin Oncol 24:1052-1056
18. Robertson JFR, Howell A, Gorbunova VA et al (2005) Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant. Breast Cancer Res Treat 92:169-174
19. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 3:205-216
20. Robertson JF, Howell A, Buzdar A et al (1999) Static disease on anastrozole provides similar benefit as objective response in patients with advanced breast cancer. Breast Cancer Res Treat 58:157-162
21. Vergote I, Robertson JFR, Kleeberg U et al (2003) Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy. Breast Cancer Res Treat 79:207-211